Eurofins Scientific Acquires 90,000 of Its Own Shares Over Five Trading Days
Eurofins Scientific has acquired 90,000 of its own shares between December 15 and December 19, 2025, according to a statement released this Sunday. The weighted average price of the repurchases was 59.43 euros per share.
According to the company, the transactions took place over five consecutive sessions on Euronext Paris. On December 15, 20,000 shares were repurchased at an average price of 58.17 euros. The following day, an identical volume was acquired at 58.57 euros. On December 17, an additional 20,000 shares were purchased at 58.75 euros. The session on December 18 also involved 20,000 shares, at an average price of 60.85 euros. Finally, on December 19, 10,000 shares were repurchased at 62.19 euros, marking the highest average price during the period.
Compliance with Market Abuse Regulations
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
According to the statement, this announcement complies with the obligations under Article 5(1)(b) of European Regulation No. 596/2014 on market abuse. Full details of the individual transactions are available on the company's website in the section dedicated to investors and share buyback programs. The financial instrument in question carries the ISIN code FR0014000MR3, and the issuer's identification code is 529900JEHFM47DYY3S57. All transactions were carried out on the Euronext Paris market, identified by the MIC code XPAR.
Total Expenditure on Share Repurchases
The total amount committed by Eurofins Scientific for these repurchases is approximately 5.35 million euros, based on the communicated weighted average price. The company does not specify the purpose of these acquisitions, which can serve various financial strategies such as capital reduction, allocation of shares to employees, or price regulation. No indication is provided regarding the continuation of the program beyond the period covered by this statement.
SectorSanté · Vaccins et laboratoires de recherche›Services médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Contexte
Period
Period: 1T2026
Key reported figures
Revenue: 1789M€
Guidance from the release
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
Les informations présentées dans cet article sont fournies à titre purement indicatif et ne constituent en aucun cas une recommandation d'investissement, une incitation à acheter ou vendre un actif financier, ni un conseil en placement. Le lecteur est invité à réaliser ses propres recherches avant toute décision.
Les investissements en bourse comportent des risques, notamment de perte en capital. La performance passée d'un actif ou d'un marché ne présage en rien de ses performances futures. Toute décision d'investissement doit être prise en tenant compte de votre situation financière personnelle, de vos objectifs et de votre tolérance au risque.
